Evaluation of a new penetration enhancer 1-[2-(decylthio)ethyl]azacyclopentan-2-one (HPE-101).
A new compound, 1-[2-(decylthio)ethyl]azacyclopentan-2-one (HPE-101) was synthesized, and its skin penetration enhancing activity was examined by using 14C-indomethacin as a penetrant. A solution of HPE-101 and indomethacin was applied to a cloth pad affixed onto an adhesive tape to give a HPE-101 patch, and the patch was applied to hairless mouse skin. The amount of percutaneously absorbed indomethacin was determined by measuring the radioactivity excreted in urine for 24 h after application. 1) Azone and decylmethyl sulfoxide, enhanced markedly the percutaneous absorption of indomethacin when the propylene glycol-ethanol (9:1 v/v) mixture was used as the solvent. 2) Among various penetration enhancers dissolved in the indomethacin solutions and applied to screen for penetration enhancing activity, HPE-101 was found to be the most prominent. 3) Solvents containing more than 3% (w/w) of HPE-101 produced a plateau level of the penetration enhancing activity. 4) Daily application of 1% (w/w) solutions of HPE-101 or Azone increased the daily excretion of indomethacin significantly above the level excreted on the previous day. However, repeated daily application beyond 3 d gave a steady state excretion of indomethacin. 5) The mouse skin was pretreated with 3% (w/w) solutions of HPE-101 or Azone for 24 h on the 1st day, and the indomethacin solution was applied for 24 h on the 3rd day and 7th day to examine the recovery of skin barrier function. Enhanced excretion of indomethacin was still noted on the 3rd day, but enhancement was not observed on the 7th day.
Yano
T
T
Research Laboratories, Hisamitsu Pharmaceutical Co., Inc., Saga, Japan.
Higo
N
N
Furukawa
K
K
Tsuji
M
M
Noda
K
K
Otagiri
M
M
D000818:Animals; D001381:Azepines / Q000494:pharmacology; D004337:Drug Carriers / Q000494:pharmacology*; D005260:Female; D007213:Indomethacin / Q000493:pharmacokinetics / Q000652:urine; D051379:Mice; D008812:Mice, Hairless; D011758:Pyrroles / Q000494:pharmacology*; D012869:Skin Absorption / Q000187:drug effects*; D012997:Solvents
D001381:Azepines; D004337:Drug Carriers; D011758:Pyrroles; D012997:Solvents; C035229:laurocapram; C075725:1-(2-(decylthio)ethyl)azacyclopentane-2-one; D007213:Indomethacin